A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with
previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain
and extra-terminal (BET) proteins.